MarketsPublished Oct 13, 2026, 11:36 AM ETUpdated Oct 13, 2026, 1:24 PM ET5 outlets

FTC and states accuse Martin Shkreli of violating lifetime pharma industry ban

By Crosswire News · AI-assisted summary of reporting by the outlets linked below

Image from MarketWatch's coverage: ‘Pharma Bro’ Martin Shkreli is in trouble with regulators again, this time for influencing biopharma stocks

The FTC and several states have filed a contempt claim alleging that Martin Shkreli broke a lifetime ban from the pharmaceutical industry. He was barred after a trial found he orchestrated an illegal scheme to maintain a monopoly on the drug Daraprim. One report says he has been weighing in on biopharma stocks despite the prohibition.

Headline and summary written by AI from the articles below. AI can make mistakes, so check the original articles before relying on a detail.

Coverage · 3 sources

CNBCMartin Shkreli violated lifetime pharma industry ban, FTC and states say in contempt claim
MarketWatch‘Pharma Bro’ Martin Shkreli is in trouble with regulators again, this time for influencing biopharma stocks
Investing.comMartin Shkreli violated lifetime pharma industry ban, FTC and states say